Skip to main content

Table 3 The comparison of first-line treatments for patients with soft tissue sarcoma

From: Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis

Chemotherapy regimen

Overall response

(CR + PR)

Adverse events

(> Grade3)

Doxorubicin monotherapy [9]

14%

LP = 18%, FN = 13%,

AN = 4%, TP = 0.4%

Doxorubicin + ifosfamide [9]

26%

LP = 43%, FN = 46%,

AN = 35%, TP = 33%

Gemcitabine + docetaxel [10]

20%

LP = 7%, FN = 12%,

AN = 6%, TP = 0%

Current protocol

36%

LP = 96%, FN = 68%,

AN = 68%, TP = 48%

  1. CR complete response, PR partial response, LP leukopenia, FN febrile neutropenia, AN anemia, TP thrombocytopenia
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us